Immuno-Oncology News Articles | Page 2

DDR Alterations Associated With Increased Anti-PD-1/PD-L1  Activity in Bladder Cancer
Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma. 
Optimizing Immunotherapy in Lung Cancer
Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.
Pembrolizumab Active in Thymic Carcinoma
Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of chemotherapy. 
Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC
George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.
Immunotherapy Trials Offer Hope in Advanced Penile Cancer
Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer. 
Pembrolizumab Continues to Demonstrate Long-Term Efficacy in Melanoma
The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma.
FDA Approves Durvalumab for Locally Advanced NSCLC
The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.
Pembrolizumab Plus SBRT Active in Advanced Solid Tumors
The addition of pembrolizumab to stereotactic body radiotherapy induced an objective response rate of 13.2% among patients with advanced solid tumors.
Immunotherapy Poised to Move Forward Into Stage III NSCLC
A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.
Joaquim Bellmunt, MD, PhD, discusses the updated pembrolizumab findings, as well as the future of immunotherapy in bladder cancer.
Publication Bottom Border
Border Publication